Answers are grounded in this paper and cite their sources.
Real-world findings show high adherence and favorable tolerability in individuals with vulnerabilities, indicating potential of cabotegravir for HIV prevention.
Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation. Participants were prioritised based on vulnerabilities compromising oral pre-exposure prophylaxis (PrEP), such as poor adherence, comorbidities and behavioural barriers. Adherence to injections exceeded 95%, tolerability was favourable and only 1.5% discontinued for drug-related reasons. These findings demonstrate the feasibility of CAB-LA in European clinical services and support its use in specific populations.
No takes yet. Share an insight, caveat, or question.
Moschese et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: